Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05160922

Crizotinib Continuation Clinical Study

CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES

Status
Active Not Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
27 (actual)
Sponsor
Pfizer · Industry
Sex
All
Age
0 Years
Healthy volunteers
Not accepted

Summary

The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.

Detailed description

Participants not previously enrolled or who have discontinued study treatment or safety follow-up in a current Pfizer sponsored crizotinib clinical study are not eligible for participation in this continuation study.

Conditions

Interventions

TypeNameDescription
DRUGcrizotinibcrizotinib oral treatment

Timeline

Start date
2021-12-27
Primary completion
2028-03-21
Completion
2028-03-21
First posted
2021-12-16
Last updated
2026-03-30

Locations

13 sites across 5 countries: China, Italy, Japan, Russia, Taiwan

Regulatory

Source: ClinicalTrials.gov record NCT05160922. Inclusion in this directory is not an endorsement.